Then they were divided into 5 groups in random according to their weights and each group had 10 mice including 5 male and 5 female. B was chronic bronchitis model group. C was higher dose XQM-treated group, D was lower dose XQM-treated group, E was positive control group, which was administered nucleic acid and casein hydrolysate composite oral medicine (NACH), F is XQM&NACH-treated group.
(3) Compared with the chronic bronchitis model group, the total T lymphocytes (CD3+) are increased significantly (p<0.01),and the level of CD4+, CD4+/CD8+ is increased significantly in two XQM-treated groups, and XQM&NACH-treated group (p<0.01), and there is the obvious relationship between the dose and the effect.
(4) Compared with the chronic bronchitis model group, the activity of S-100+ cell is decreased significantly in two XQM-treated groups, NACH-treated group and XQM&NACH-treated groupConclusions:(1) The observation of the pathologic appearance shows: XQM has the obviously therapeutic efficacy to the inflammatory harm in chronic bronchitis mice, can alleviate the inflammatory reaction in chronic bronchitis mice.